

## EUROBIO SCIENTIFIC EXPANDS ITS ONCOLOGY DIAGNOSTICS PORTFOLIO WITH A DISTRIBUTION AGREEMENT WITH CANHELP GENOMICS

Paris, May 26, 2026

**Eurobio Scientific** (FR0013240934, ALERS), a leading French group in specialty in vitro medical diagnostics and life sciences, announces the signing of a distribution agreement with Canhelp Genomics, a company specialized in molecular diagnostics for oncology.

Under this agreement, Eurobio Scientific will distribute two genomic assays, Canhelp-UCa and Canhelp-Origin, in France, Germany, the United Kingdom, Austria, Switzerland, and the Benelux countries, building on the existing partnership in Italy. The products will be commercialized by the Group's Oncology team, further strengthening its position in precision oncology and expanding the portfolio of molecular diagnostic solutions.

**The Canhelp-Uca test** is a molecular diagnostic CE-IVD assay for the auxiliary diagnosis and recurrence monitoring of urothelial carcinoma. Using an eight-gene RNA signature from a simple urine sample, the test delivers highly accurate molecular insights without the need for invasive procedures.<sup>1,2</sup> For patients, the key benefit lies in a simpler and less invasive testing experience, with the potential to reduce the frequency of burdensome procedures and improve overall quality of care.

**The Canhelp-Origin test** is a CE-IVD assay designed for patients presenting with metastatic cancer in whom the primary tumor site cannot be identified (Cancer of Unknown or Uncertain Primary) through standard diagnostic procedures.<sup>3</sup> For patients, a reduction in diagnostic uncertainty supports more confident clinical decision-making and a more personalized approach to their cancer care. The landmark FUDAN CUP-001 randomized controlled trial, published in *The Lancet Oncology*, demonstrated that site-specific therapy guided by Canhelp-Origin significantly improved patients' outcomes.<sup>4</sup>

Both assays are performed on the same RT-qPCR platform that is also used for established tests such as EndoPredict® and Prolaris®, enabling integration into existing laboratory workflows and leveraging Eurobio Scientific's expertise in decentralized molecular testing.

"We are delighted to partner with Canhelp Genomics to bring their advanced molecular diagnostic solutions to our markets," said Denis Fortier, CEO of Eurobio Scientific. "These tests complement our existing oncology portfolio and support clinicians and patients in making informed, precision-based treatment decisions."

"This partnership with Eurobio Scientific is a defining moment in our mission to make precision oncology accessible to patients worldwide," stated Dr. Qinghua Xu, CEO of Canhelp Genomics. "Eurobio Scientific's proven expertise in molecular diagnostics commercialization and their extensive European network make them the ideal partner to bring our solutions to the clinicians and patients who need them most."

### References

1. Xu H, et al. Development and prospective validation of a multitarget urine RNA assay for noninvasive detection of urothelial carcinoma. *iScience*, 2025, 28(12).
2. Zhang H, et al. Large-scale Prospective Validation Study of a Multiplex RNA Urine Test for Noninvasive Detection of Upper Tract Urothelial Carcinoma. *Eur Urol Oncol*. 2024, 7(6): 1384-1393.
3. Sun W, et al. Clinical validation of a 90-gene expression test for tumor tissue of origin diagnosis: a large-scale multicenter study of 1417 patients. *J Trans Med*. 2022, 20(1): 114.
4. Liu X, et al. Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial. *Lancet Oncol*. 2024, 25(8): 1092-1102.

### About Eurobio Scientific

Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, oncology, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 290 employees and four production units based in the Paris region, in Germany, in the Netherlands and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany, Antwerp Belgium, Utrecht in The Netherlands and Milan in Italy.

Eurobio Scientific's reference shareholder is the Eurobio Development Holding company which brings together its two directors, Jean-Michel Carle and Denis Fortier, alongside IK Partners, "Pépites et Territoires" by AXA & NextStage AM investment program managed by NextStage AM as well as Jérôme de Castrie.

For more information, please visit: [www.eurobio-scientific.com](http://www.eurobio-scientific.com)

The company is publicly listed on the Euronext Growth market in Paris

Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label. Symbol: ALERS - ISIN Code: FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP

### About Canhelp Genomics

Canhelp Genomics is a leading AI-powered precision oncology diagnostics company. Built on a full-stack technology platform integrating proprietary RNA molecular diagnostics, digital pathology, and intelligent instrumentation, the company has established end-to-end capabilities spanning R&D, regulatory, manufacturing, and commercialization, supported by 70+ patents and multiple NMPA and CE-IVD certifications. Canhelp Genomics has developed a differentiated product portfolio that includes: Canhelp-Origin, the only pan-cancer tumor origin diagnostic dual-approved by NMPA and CE-IVD, with Phase 3 evidence published in *The Lancet Oncology*; Canhelp-UCa, the first urine RNA test to achieve NMPA and CE-IVD dual certification for non-invasive urothelial carcinoma detection; Canhelp-MSI, an NMPA Breakthrough Device for AI-based microsatellite instability detection in digital pathology; Canhelp-MDS, a next-generation AI-powered tumor cell micro-dissection system. Canhelp Genomics products are adopted by leading hospitals and laboratories across China, and commercialized in multiple markets across Asia, Europe, and Oceania through strategic distribution partnerships. For further information, visit: [www.canhelpgenomics.com](http://www.canhelpgenomics.com)

### Contacts

Groupe Eurobio Scientific

Denis Fortier, Chairman and CEO Olivier Bosc, Deputy CEO/ CFO Tel. +33(0) 1 69 79 64 80

### Actus

Mathieu Calleux Investors Relations

Tel. +33(1) 53 65 68 68 - [eurobio-scientific@actus.fr](mailto:eurobio-scientific@actus.fr)

